Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline fab antivenom

Leslie V Boyer, Steven A. Seifert, Jeffrey S. Cain

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Recurrent local and coagulopathic effects worsening after clinical improvement) have been described after treatment with Fab antivenom for envenomation by North American crotaline snakes. Although similar phenomena have been described previously in snakebite, few studies have examined recurrence or its management. Recurrence is consistent with known venom and antivenom kinetics and dynamics. The clinical significance of late coagulopathy after snakebite is uncertain, but clinically significant bleeding is a possibility. Prevention and treatment of recurrence with Fab antivenom require repeated dosing for at least 18 hours, with close monitoring of at risk patients in the follow-up period. Duration of therapy depends on individual risk factors and coagulation response.

Original languageEnglish (US)
Pages (from-to)196-201
Number of pages6
JournalAnnals of Emergency Medicine
Volume37
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Antivenins
Snake Bites
Passive Immunization
Guidelines
Recurrence
Snakes
Venoms
Therapeutics
Hemorrhage

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Recurrence phenomena after immunoglobulin therapy for snake envenomations : Part 2. Guidelines for clinical management with crotaline fab antivenom. / Boyer, Leslie V; Seifert, Steven A.; Cain, Jeffrey S.

In: Annals of Emergency Medicine, Vol. 37, No. 2, 2001, p. 196-201.

Research output: Contribution to journalArticle

@article{08f76ecb938a4a0ab0675e259115049c,
title = "Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline fab antivenom",
abstract = "Recurrent local and coagulopathic effects worsening after clinical improvement) have been described after treatment with Fab antivenom for envenomation by North American crotaline snakes. Although similar phenomena have been described previously in snakebite, few studies have examined recurrence or its management. Recurrence is consistent with known venom and antivenom kinetics and dynamics. The clinical significance of late coagulopathy after snakebite is uncertain, but clinically significant bleeding is a possibility. Prevention and treatment of recurrence with Fab antivenom require repeated dosing for at least 18 hours, with close monitoring of at risk patients in the follow-up period. Duration of therapy depends on individual risk factors and coagulation response.",
author = "Boyer, {Leslie V} and Seifert, {Steven A.} and Cain, {Jeffrey S.}",
year = "2001",
doi = "10.1067/mem.2001.113134",
language = "English (US)",
volume = "37",
pages = "196--201",
journal = "Annals of Emergency Medicine",
issn = "0196-0644",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Recurrence phenomena after immunoglobulin therapy for snake envenomations

T2 - Part 2. Guidelines for clinical management with crotaline fab antivenom

AU - Boyer, Leslie V

AU - Seifert, Steven A.

AU - Cain, Jeffrey S.

PY - 2001

Y1 - 2001

N2 - Recurrent local and coagulopathic effects worsening after clinical improvement) have been described after treatment with Fab antivenom for envenomation by North American crotaline snakes. Although similar phenomena have been described previously in snakebite, few studies have examined recurrence or its management. Recurrence is consistent with known venom and antivenom kinetics and dynamics. The clinical significance of late coagulopathy after snakebite is uncertain, but clinically significant bleeding is a possibility. Prevention and treatment of recurrence with Fab antivenom require repeated dosing for at least 18 hours, with close monitoring of at risk patients in the follow-up period. Duration of therapy depends on individual risk factors and coagulation response.

AB - Recurrent local and coagulopathic effects worsening after clinical improvement) have been described after treatment with Fab antivenom for envenomation by North American crotaline snakes. Although similar phenomena have been described previously in snakebite, few studies have examined recurrence or its management. Recurrence is consistent with known venom and antivenom kinetics and dynamics. The clinical significance of late coagulopathy after snakebite is uncertain, but clinically significant bleeding is a possibility. Prevention and treatment of recurrence with Fab antivenom require repeated dosing for at least 18 hours, with close monitoring of at risk patients in the follow-up period. Duration of therapy depends on individual risk factors and coagulation response.

UR - http://www.scopus.com/inward/record.url?scp=0035134542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035134542&partnerID=8YFLogxK

U2 - 10.1067/mem.2001.113134

DO - 10.1067/mem.2001.113134

M3 - Article

C2 - 11174239

AN - SCOPUS:0035134542

VL - 37

SP - 196

EP - 201

JO - Annals of Emergency Medicine

JF - Annals of Emergency Medicine

SN - 0196-0644

IS - 2

ER -